Clinical trial
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Parallel Group Phase III Study to Evaluate the Efficacy and Safety of STN1013800 Ophthalmic Solution in Chinese Patients With Acquired Blepharoptosis
NCT06683651 is registered in ClinicalTrials.gov with Santen Pharmaceutical Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized, Double-Masked, Placebo-Controlled Parallel Group Phase III Study to Evaluate the Efficacy and Safety of STN1013800 Ophthalmic Solution in Chinese Patients With Acquired Blepharoptosis
- Lead sponsor
- Santen Pharmaceutical Co., Ltd.
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- October 22, 2024
- Completion date
- June 30, 2026
- Enrollment
- 180 (estimated)
- Sites
- 23
Conditions
As the registry lists them; a condition with its own page is linked.